Anastrozole
Anastrozole (Arimidex): FDA approval for breast cancer in postmenopausal women, label warnings on heart, bone and cholesterol, and WADA status.
FDA-approved, prescription only · Evidence grade A · Reviewed
- FDA-approvedBreast cancerPostmenopausal women
Anastrozole (Arimidex). Aromatase inhibitor.
AFDA-approved, prescription only. Evidence grade A: approved, large human trials.
What is Anastrozole?
Anastrozole is an oral, nonsteroidal aromatase inhibitor that lowers the body's estrogen levels.
Is Anastrozole FDA-approved?
FDA first approved Arimidex (NDA 020541) in 1995. It is approved for breast cancer in postmenopausal women, including adjuvant treatment of early hormone receptor positive disease and treatment of advanced disease. Generics are sold, and it is prescription only. Use in men or to manage steroid side effects is not an approved use.
What does the evidence show for Anastrozole?
Large randomized trials in postmenopausal women with breast cancer support the approved uses. The label states that effectiveness was not shown in studies of certain pubertal children.
What are the known risks of Anastrozole?
The label has no boxed warning. It warns of more ischemic heart events in women with existing ischemic heart disease, lower bone mineral density, higher cholesterol, and harm to an unborn baby. WADA prohibits aromatase inhibitors at all times in class S4, hormone and metabolic modulators.
How is Anastrozole measured?
A tablet, so there is nothing to draw or calculate.
Sources: FDA: Arimidex prescribing information (2024); WADA: The Prohibited List. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.